Hims & Hers Health (NYSE:HIMS) Issues Quarterly Earnings Results

Hims & Hers Health (NYSE:HIMS) announced its quarterly earnings data on Monday. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.03), FiscalAI reports. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The firm had revenue of $890.37 million during the quarter, compared to analyst estimates of $892.88 million.

Hims & Hers Health Stock Down 11.9%

Hims & Hers Health stock traded down $3.10 during midday trading on Monday, hitting $22.90. 48,022,495 shares of the stock were exchanged, compared to its average volume of 22,224,598. Hims & Hers Health has a 52-week low of $13.74 and a 52-week high of $42.70. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21. The business’s 50-day moving average price is $28.43 and its 200-day moving average price is $26.94. The stock has a market capitalization of $5.34 billion, a price-to-earnings ratio of -36.34 and a beta of 2.53.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. TD Cowen upped their target price on Hims & Hers Health from $25.00 to $30.00 and gave the stock a “hold” rating in a research report on Tuesday, August 11th. Barclays reduced their price target on shares of Hims & Hers Health from $39.00 to $35.00 and set an “overweight” rating for the company in a research report on Friday, August 21st. Needham & Company LLC boosted their price objective on Hims & Hers Health from $35.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Morgan Stanley raised their target price on Hims & Hers Health from $21.00 to $28.00 and gave the company an “equal weight” rating in a report on Tuesday, August 11th. Finally, Bank of America raised their target price on Hims & Hers Health from $30.00 to $32.00 and gave the company a “neutral” rating in a report on Tuesday, August 11th. Three research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $32.43.

Insider Buying and Selling at Hims & Hers Health

In other news, insider Soleil Boughton sold 3,462 shares of the company’s stock in a transaction that occurred on Wednesday, October 28th. The stock was sold at an average price of $27.60, for a total value of $95,551.20. Following the completion of the transaction, the insider directly owned 293,886 shares of the company’s stock, valued at $8,111,253.60. This represents a 1.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Oluyemi Okupe sold 2,000 shares of the stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $29.70, for a total value of $59,400.00. Following the sale, the chief financial officer directly owned 234,527 shares of the company’s stock, valued at $6,965,451.90. The trade was a 0.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 133,905 shares of company stock worth $3,826,977. Insiders own 11.76% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a consumer-focused telehealth platform that connects patients with licensed healthcare providers and offers access to treatments and wellness products. Its services include online consultations, prescription care and over-the-counter products.

The company serves a range of health needs, including hair loss, sexual health, skin care, mental health and weight management. Its platform also offers primary care and other services, with offerings varying by location and individual eligibility.

Founded in 2017, the company initially launched its Hims brand and later introduced Hers, expanding its services to a broader audience.